Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HRS-8080 or Ruzaltatug Rezetecan Combinations in Advanced Breast Cancer
NCT06222879Phase 2Recruiting
- Sponsor
- Shandong Suncadia Medicine Co., Ltd.
- Start
- Feb 2024
- Primary completion
- Oct 2026
- Modality
- Antibody-Drug Conjugates (ADCs), Molecular Glues
- Countries
- 1
01
Overview
A Phase 2 trial of HRS-8080, ruzaltatug rezetecan in breast cancer, sponsored by Shandong Suncadia Medicine Co., Ltd.. Started Feb 2024; status: recruiting.
02
Drugs
HRS-8080ruzaltatug rezetecan
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT06222879.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06222879.